Journey Medical Corporation (DERM)
NASDAQ: DERM · Real-Time Price · USD
5.26
+0.06 (1.15%)
Apr 14, 2026, 4:00 PM EDT - Market closed
Journey Medical Revenue
In the year 2025, Journey Medical had annual revenue of $61.86M with 10.20% growth. Journey Medical had revenue of $16.08M in the quarter ending December 31, 2025, with 18.05% growth.
Revenue (ttm)
$61.86M
Revenue Growth
+10.20%
P/S Ratio
2.32
Revenue / Employee
$1,066,517
Employees
58
Market Cap
143.76M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 61.86M | 5.72M | 10.20% |
| Dec 31, 2024 | 56.13M | -23.05M | -29.11% |
| Dec 31, 2023 | 79.18M | 5.51M | 7.48% |
| Dec 31, 2022 | 73.67M | 10.54M | 16.69% |
| Dec 31, 2021 | 63.13M | 18.60M | 41.78% |
| Dec 31, 2020 | 44.53M | 9.61M | 27.52% |
| Dec 31, 2019 | 34.92M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Organogenesis Holdings | 564.17M |
| Evolus | 297.18M |
| Aurora Cannabis | 272.13M |
| Organigram Global | 204.21M |
| Lifecore Biomedical | 129.46M |
| Assertio Holdings | 118.71M |
| Anika Therapeutics | 112.82M |
| Alpha Teknova | 40.52M |
DERM News
- 12 days ago - Journey Medical Corporation Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewsWire
- 20 days ago - Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 27 days ago - Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 - GlobeNewsWire
- 4 months ago - Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology - GlobeNewsWire
- 5 months ago - Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 5 months ago - Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025 - GlobeNewsWire
- 6 months ago - Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference - GlobeNewsWire
- 6 months ago - Journey Medical Corporation to Participate in October 2025 Investor Conferences - GlobeNewsWire